Small Molecules

12 Apr 2019 Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
11 Apr 2019 Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
11 Apr 2019 Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
10 Apr 2019 NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
09 Apr 2019 Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration
09 Apr 2019 Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
09 Apr 2019 Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
09 Apr 2019 PIXUVRI® (pixantrone) Receives Positive CHMP Opinion to Convert Conditional Approval into Standard Marketing Authorization in Patients with Aggressive non-Hodgkin B-cell Lymphoma
09 Apr 2019 US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
09 Apr 2019 Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
08 Apr 2019 Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
08 Apr 2019 United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
06 Apr 2019 Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
05 Apr 2019 U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
05 Apr 2019 Nanobiotix announces first ever radioenhancer to receive European market approval
04 Apr 2019 EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
04 Apr 2019 VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
03 Apr 2019 Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
03 Apr 2019 Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
03 Apr 2019 Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
03 Apr 2019 Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
03 Apr 2019 Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
03 Apr 2019 Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
02 Apr 2019 Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
02 Apr 2019 Novel First-In-Class FLIP Inhibitors for the Treatment of Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up